DE60315863D1 - Die verwendung von dem a3 adenosin rezeptor als marker eines krankheitszustandes - Google Patents

Die verwendung von dem a3 adenosin rezeptor als marker eines krankheitszustandes

Info

Publication number
DE60315863D1
DE60315863D1 DE60315863T DE60315863T DE60315863D1 DE 60315863 D1 DE60315863 D1 DE 60315863D1 DE 60315863 T DE60315863 T DE 60315863T DE 60315863 T DE60315863 T DE 60315863T DE 60315863 D1 DE60315863 D1 DE 60315863D1
Authority
DE
Germany
Prior art keywords
adenosine receptor
marker
sickness state
expression level
sickness
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60315863T
Other languages
English (en)
Other versions
DE60315863T2 (de
Inventor
Pnina Fishman
Lea Madi
Yehuda Sara Bar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Can Fite Biopharma Ltd
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Application granted granted Critical
Publication of DE60315863D1 publication Critical patent/DE60315863D1/de
Publication of DE60315863T2 publication Critical patent/DE60315863T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60315863T 2002-10-22 2003-10-21 A3ar als ein marker für einen erkrankungszustand Expired - Fee Related DE60315863T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42003802P 2002-10-22 2002-10-22
US420038P 2002-10-22
PCT/IL2003/000856 WO2004038419A1 (en) 2002-10-22 2003-10-21 The use of the a3 adenosine receptor as a marker for a diseased state

Publications (2)

Publication Number Publication Date
DE60315863D1 true DE60315863D1 (de) 2007-10-04
DE60315863T2 DE60315863T2 (de) 2008-05-15

Family

ID=32176505

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60315863T Expired - Fee Related DE60315863T2 (de) 2002-10-22 2003-10-21 A3ar als ein marker für einen erkrankungszustand

Country Status (7)

Country Link
US (1) US20040137477A1 (de)
EP (1) EP1554583B1 (de)
JP (1) JP2006503574A (de)
AT (1) ATE371191T1 (de)
AU (1) AU2003274648A1 (de)
DE (1) DE60315863T2 (de)
WO (1) WO2004038419A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1766060A4 (de) * 2004-05-14 2007-11-28 King Pharmaceuticals Res & Dev Verfahren zur diagnose und prognostizierung von soliden tumoren und melanom
US20080051365A1 (en) * 2004-12-02 2008-02-28 Can-Fite Biopharma Ltd. Treatment of Inflammation
CA2586773C (en) 2004-12-02 2018-03-27 Can-Fite Biopharma Ltd. A biological marker for inflammation
WO2007063539A1 (en) * 2005-11-30 2007-06-07 Can-Fite Biopharma Ltd. Therapeutic uses of a3 adenosine receptor antibodies
DK1983990T3 (da) * 2006-01-26 2011-07-11 Us Gov Health & Human Serv Allosteriske A3-adenosin-receptormodulatorer
WO2008056361A1 (en) * 2006-11-09 2008-05-15 Can-Fite Biopharma Ltd. A biological marker for psoriasis
PT2137202T (pt) 2007-03-14 2017-10-02 Can-Fite Biopharma Ltd Processo para a síntese de ib-meca
WO2010020981A1 (en) * 2008-08-19 2010-02-25 Universiteit Leiden A3 adenosine receptor allosteric modulators
IL272078A (en) * 2020-01-16 2021-07-29 Can Fite Biopharma Ltd Cannabinoids for use in therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543291A (en) * 1993-01-29 1996-08-06 Dana Farber Cancer Institute Method of detecting carcinoma
US6063376A (en) * 1995-01-13 2000-05-16 Human Genome Sciences, Inc. Human deoxycytidine kinase 2
EP2014772A3 (de) * 1996-04-05 2009-05-27 Antonio Giordano Verfahren zur Diagnose und Prognose von Krebs
WO2000002861A1 (en) * 1998-07-10 2000-01-20 The United States Of America, Represented By Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists
US6448253B1 (en) * 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist

Also Published As

Publication number Publication date
DE60315863T2 (de) 2008-05-15
WO2004038419A1 (en) 2004-05-06
JP2006503574A (ja) 2006-02-02
AU2003274648A1 (en) 2004-05-13
US20040137477A1 (en) 2004-07-15
EP1554583A1 (de) 2005-07-20
ATE371191T1 (de) 2007-09-15
EP1554583B1 (de) 2007-08-22

Similar Documents

Publication Publication Date Title
AR040748A1 (es) Un metodo y un sistema para posicionar unidades moviles utilizando mediciones de angulo
DE60315863D1 (de) Die verwendung von dem a3 adenosin rezeptor als marker eines krankheitszustandes
ES2572372T3 (es) Método de diagnóstico de enfermedades neurodegenerativas basado en la medición de los niveles o de la actividad de SIRT1
ATE271691T1 (de) Verfahren zum nachweis der effektivität einer krebstherapie
TW200710705A (en) Touch location determination using bending mode sensors and multiple detection techniques
ATE340593T1 (de) Ermittlung der auswirkung von einem clostridial toxin auf muskeln
CY1108092T1 (el) Ενωσεις και μεθοδοι για την αναστολη της μιτωτικης προοδου με την αναστολη της κινασης aurora
DK1866650T3 (da) Neurodegenerative markører for depression
MX2007016136A (es) Metodo para diagnosticar la enfermedad de alzheimer.
ATE426662T1 (de) Feedback resistante mevalonate kinase
PL2021794T3 (pl) Zastosowanie białka S100A 12 jako markera raka okrężnicy i odbytnicy
WO2005024631A3 (en) Creating and checking runtime data types
WO2005001046A3 (en) Methods for predicting the course of a malignant disease
ATE306265T1 (de) Benzothiazolderivate als adenosin-rezeptor- liganden
MY142283A (en) Diagnosis and treatment of cancers and other conditions
ATE403656T1 (de) Xanthinderivate als a2b- adenosinrezeptorantagonisten
ATE447174T1 (de) Verfahren zum direkten nachweis einzelner methotrexatmetabolite
DK1791973T3 (da) DOT1-histonmethyltransferaser som et target til at identificere terapeutiske midler mod leukæmi
DE602005013430D1 (de) Verwendung von asc als marker für kolorektalkarzinome
ATE365327T1 (de) Verfahren zum nachweis von zelltod mittels cytochrom c.
ITRM20050314A1 (it) Apparato di controllo in tempo reale del ciclo di lavorazione per l'estrazione a freddo dell'olio di oliva.
ATE534902T1 (de) Replikationsproteinn ciz1
WO2005002414A3 (en) Prognosis determination in ewing sarcoma patients by means of genetic profiling
DE60315211D1 (de) Leicht einstellbares Hilfspedalsystem für Tasteninstrument
ATE466958T1 (de) Klassifizierung von kolonkrebs

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee